Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms.
1/5 보강
Paclitaxel (PTX), a member of the taxane family of anticancer drugs, is considered one of the most effective chemotherapeutic agents used worldwide.
APA
Naeem AG, Fawzi SF, et al. (2026). Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms.. Naunyn-Schmiedeberg's archives of pharmacology, 399(2), 1721-1750. https://doi.org/10.1007/s00210-025-04480-6
MLA
Naeem AG, et al.. "Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms.." Naunyn-Schmiedeberg's archives of pharmacology, vol. 399, no. 2, 2026, pp. 1721-1750.
PMID
40864255 ↗
Abstract 한글 요약
Paclitaxel (PTX), a member of the taxane family of anticancer drugs, is considered one of the most effective chemotherapeutic agents used worldwide. It is widely used in the treatment of solid tumors, including non-small-cell lung, colon, breast, ovarian, prostate, and bladder cancers. Its anticancer activity involves multiple mechanisms: mitotic arrest, mitochondrial damage, and apoptosis induction. Hence, being a non-targeted drug, PTX is associated with many types of toxicities, limiting its effectiveness and affecting the patient's quality of life. Unfortunately, this may result in treatment modifications or even discontinuation. The common clinical toxicities encountered with PTX include cognitive impairment, peripheral neuropathy, testicular toxicity, pulmonary toxicity, cardiotoxicity, hepatotoxicity, and nephrotoxicity. However, the underlying mechanisms of these toxicities remain elusive. This review article focuses on PTX-induced toxicities and the suggested detailed pathological mechanisms underlying each one.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.